ESMO 2023 Abstract for Trial #21-46

Long-term efficacy, safety and PK data of TH1902 (sudocetaxel zendusortide) in solid tumors: A novel SORT1-targeting peptide-drug-conjugate (PDC)

Wednesday, June 19, 2024

Dr. Minal Barve

Read the Story Here

Click above link to view abstract.

ASCO 2024 Poster for Trial 21-46

ASCO 2024 Poster for Trial 21-46

Click to view ASCO 2024 Poster for Trial 21-46 Full Size.

Related Abstracts

Discover more abstracts for our trials.

Preliminary Clinical Activity of RMC-6236, a First-in-Class, RAS-Selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC)

Aug 23, 2024

Dr. Minal Barve

STX-478, a mutant-selective PI3Kαinhibitor clinical candidate with a best-in-class profile: Pharmacology and therapeutic activity as monotherapy and in combination in breast cancer xenograft models

Aug 21, 2024

Dr. Douglas Orr

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression

Aug 21, 2024

Dr. Minal Barve
See All Posts